We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

45 hedge funds and large institutions have $113M invested in MoonLake Immunotherapeutics in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

5% more funds holding

Funds holding: 43 → 45 (+2)

1.73% more ownership

Funds ownership: 94.04% → 95.77% (+1.7%)

2% more capital invested

Capital invested by funds: $111M → $113M (+$1.75M)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
45
Holders Change
+2
Holders Change %
+4.65%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
5
Reduced
5
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$11.9M
2
Marshall Wace
Marshall Wace
United Kingdom
+$5.3M
3
6CM
683 Capital Management
New York
+$4.37M
4
CS
Credit Suisse
Switzerland
+$3.69M
5
AWG
Alpha Wave Global
New York
+$3.06M

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$7.39M
2
RCM
RA Capital Management
Massachusetts
-$6.96M
3
GTC
Ghost Tree Capital
New York
-$4.94M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$4.78M
5
FC
Finepoint Capital
Massachusetts
-$3.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCFM
26
Cohen & Co Financial Management
New York
$989K +$994K +100,000 New
JG
27
Jefferies Group
New York
$774K +$778K +78,308 New
PMAM
28
Picton Mahoney Asset Management
Ontario, Canada
$693K – – –
IPCP
29
Iron Park Capital Partners
New York
$615K +$618K +62,216 New
Millennium Management
30
Millennium Management
New York
$551K – – –
SSA
31
Schonfeld Strategic Advisors
New York
$496K +$498K +50,106 New
PCM
32
Prelude Capital Management
New York
$495K – – –
TD Asset Management
33
TD Asset Management
Ontario, Canada
$443K – – –
MWM
34
Meridian Wealth Management
Kentucky
$416K – – –
MF
35
Magnetar Financial
Illinois
$370K -$240K -24,172 -39%
RCM
36
Radcliffe Capital Management
Pennsylvania
$249K -$10 -1 -0%
ECM
37
ExodusPoint Capital Management
New York
$249K +$1.99K +200 +0.8%
Nomura Holdings
38
Nomura Holdings
Japan
$225K – – –
CC
39
Caxton Corporation
New Jersey
$158K – – –
WAM
40
Weiss Asset Management
Massachusetts
$148K +$149K +15,000 New
HF
41
HRT Financial
New York
$141K +$70 +7 +0%
RL
42
RPO LLC
Connecticut
$135K +$135K +13,600 New
Morgan Stanley
43
Morgan Stanley
New York
$133K – – –
AC
44
Antara Capital
New York
$62K +$62.1K +6,246 New
TRCT
45
Tower Research Capital (TRC)
New York
$2K +$755 +76 +65%
RI
46
RTW Investments
New York
– -$7.39M -750,000 Closed
RCM
47
RA Capital Management
Massachusetts
– -$6.96M -700,000 Closed
GTC
48
Ghost Tree Capital
New York
– -$4.94M -500,000 Closed
Wellington Management Group
49
Wellington Management Group
Massachusetts
– -$4.78M -483,887 Closed
FC
50
Finepoint Capital
Massachusetts
– -$3.77M -382,400 Closed
1
2
3

MLTX Hedge Fund Activity: Q4 2021 in Review

45 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2021, worth a combined $113M — up 1.6% from $111M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new MLTX positions and 12 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $11.9M. The largest seller was RTW Investments, exiting entirely with an estimated $7.39M sold.

  • 45 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2021, up from 43 in Q3 2021.
  • Funds reported $113M of MoonLake Immunotherapeutics stock for Q4 2021, up 1.6% quarter-over-quarter.
  • 14 funds opened new MoonLake Immunotherapeutics positions in Q4 2021 and 12 closed out, a net change of +2 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q4 2021 was Fidelity Investments, an estimated $11.9M added.
  • The largest MoonLake Immunotherapeutics seller in Q4 2021 was RTW Investments, an estimated $7.39M sold.

Based on aggregated 13F filings for Q4 2021.